Reducing Peritoneal Dialysis-Related Peritonitis Rate

REFERENCES

1. ↵
   1. Broughton A,
   2. Verger C,
   3. Goffin E

   (May-Jun 2010) Pets-related peritonitis in peritoneal dialysis: companion animals or Trojan horses? Semin Dial 23(3):306–316, pmid:20636924.

   OpenUrlCrossRefPubMed
2. ↵
   1. Piraino B,
   2. Bernardini J,
   3. Brown E,
   4. et al.

   (Nov-Dec 2011) ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 31(6):614–630, pmid:21880990, Epub 2011 Aug 31.

   OpenUrlFREE Full Text
3. ↵
   1. Borg D,
   2. Shetty A,
   3. Williams D,
   4. Faber MD

   (2003) Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program. Adv Perit Dial 19:202–205, pmid:14763063.

   OpenUrlPubMed
4. ↵
   1. Shetty A,
   2. Borg D,
   3. Faber M

   (2000) Direct inoculation of the dialysate into large blood culture bottles to eliminate culture negative peritonitis [abstract]. Perit Dial Int 20:S5–S116.

   OpenUrlAbstract
5. ↵
   1. Miller TE,
   2. Findon G

   (Nov-Dec 1997) Touch contamination of connection devices in peritoneal dialysis—a quantitative microbiologic analysis. Perit Dial Int 17(6):560–567, pmid:9655155.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis

   (11, 1996) Mupirocin Study Group. J Am Soc Nephrol 7(11):2403–2408, pmid:8959632.

   OpenUrlAbstract
7. ↵
   1. Thodis E,
   2. Bhaskaran S,
   3. Pasadakis P,
   4. Bargman JM,
   5. Vas SI,
   6. Oreopoulos DG

   (May-Jun 1998) Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 18(3):261–270, pmid:9663889.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. Bernardini J,
   2. Piraino B,
   3. Holley J,
   4. Johnston JR,
   5. Lutes R

   (5, 1996) A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 27(5):695–700, pmid:8629630.

   OpenUrlPubMedWeb of Science
9. ↵
   1. McQuillan RF,
   2. Chiu E,
   3. Nessim S,
   4. et al.

   (2, 2012) A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clin J Am Soc Nephrol 7(2):297–303, pmid:22134627, Epub 2011 Dec 1.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Bernardini J,
    2. Bender F,
    3. Florio T,
    4. et al.

    (2, 2005) Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 16(2):539–545, pmid:15625071, Epub 2004 Dec 29.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Chuang YW,
    2. Shu KH,
    3. Yu TM,
    4. Cheng CH,
    5. Chen CH

    (5, 2009) Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 24(5):1603–1608, pmid:19103738, Epub 2008 Dec 22.

    OpenUrlCrossRefPubMed